• Phenytoin (5,5-diphenylimidazolidine-2,4-dione): Mechanisms

  2026-04-29

  Phenytoin is a validated inactive voltage-gated sodium channel stabilizer central to sodium channel modulation research. Its high purity and well-defined solubility make it a benchmark compound for electrophysiology assays in neurological disease models. Experimental evidence supports its use in enzyme inhibition studies with robust, reproducible parameters.

• Pexidartinib (PLX3397): Precision Modulation of Tumor Macrop

  2026-04-29

  Pexidartinib (PLX3397) empowers researchers to selectively inhibit CSF1R-mediated signaling, enabling sophisticated control of macrophage dynamics in the tumor microenvironment. This article decodes applied workflows, troubleshooting best practices, and method adaptations that maximize the translational impact of APExBIO’s Pexidartinib in advanced cancer research.

• Myriocin Mitigates dAGE-Induced Metabolic Dysfunction via Mi

  2026-04-28

  This study demonstrates that myriocin, a serine palmitoyltransferase inhibitor, reverses obesity and metabolic disturbances triggered by dietary AGEs in mice by activating AMPK-PGC1α signaling and promoting mitochondrial biogenesis. The work establishes a mechanistic link between sphingolipid inhibition and systemic metabolic improvement, offering new avenues for metabolic syndrome intervention.

• ω-Agatoxin IVA TFA: Selective Cav2.1 Blocker for Neuroprotec

  2026-04-28

  ω-Agatoxin IVA TFA is a highly specific P/Q-type calcium channel blocker with nanomolar potency. It enables precise neuronal calcium current recording and neuroprotection studies, with proven efficacy in epilepsy models.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Test

  2026-04-27

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, enabling closer recapitulation of the tumor microenvironment. The platform reveals how stromal components modulate drug responses and gene expression, providing a physiologically relevant framework for studying drug resistance and optimizing personalized therapies.

• Cinoxacin: Quinolone Antibiotic Benchmarks for Gram-Negative

  2026-04-27

  Cinoxacin is a synthetic quinolone antibiotic with potent, selective activity against Gram-negative bacteria. It inhibits bacterial DNA synthesis and is widely used in urinary tract infection research. This dossier details its mechanism, validated MIC values, and laboratory assay best practices.

• NADPH Oxidase-Derived ROS Activate L-type Ca2+ Channels in Y

  2026-04-26

  This study demonstrates that NADPH oxidase-generated reactive oxygen species (ROS) drive arterial contraction in early postnatal rats by specifically activating L-type voltage-gated Ca2+ channels, rather than by engaging Rho-kinase, PKC, or Src kinase pathways. These findings clarify developmental mechanisms of vascular tone regulation and refine strategies for Src kinase signaling pathway research.

• APOL1 Variant Evolution, APOL3 Interactions, and Isoform Imp

  2026-04-25

  This article analyzes Khalaila and Skorecki's 2025 study, which integrates APOL1 molecular evolution, splice isoform function, and APOL3 interactions to clarify the cellular mechanisms underlying APOL1-driven renal injury. Their multi-pronged approach uncovers new variant–haplotype couplings, isoform-specific activities, and protein–protein interfaces, advancing the mechanistic understanding of APOL1 cytotoxicity and guiding future research.

• Inducing Embryonic Dormancy via mTOR Inhibition Protocols

  2026-04-24

  The reference study establishes detailed in vitro protocols to induce a reversible diapause-like dormant state in mammalian embryonic cells by pharmacological inhibition of mTOR. This work enables noninvasive, scalable exploration of dormancy mechanisms and broadens the toolkit for developmental and reproductive biology research.

• L-NAME Hydrochloride: Beyond NOS Inhibition in Vascular Rese

  2026-04-24

  Explore the multifaceted role of L-NAME Hydrochloride in vascular research, from precise NOS inhibition to dissecting alternative vasorelaxation pathways. This in-depth article bridges mechanistic insights with experimental design, providing new value for experts investigating cardiovascular disease models.

• PD98059 (SKU A1663): Enhancing MAPK/ERK Pathway Research

  2026-04-23

  PD98059 (SKU A1663) is a selective and reversible MEK inhibitor trusted by biomedical researchers for dissecting the MAPK/ERK pathway. This article explores real laboratory scenarios where PD98059's reliability, reproducibility, and validated performance data provide practical solutions for cell viability, apoptosis, and neuroprotection studies.

• Cyclophilin A's Role in Cyclosporine Immunosuppression: Key

  2026-04-23

  This article analyzes the pivotal study demonstrating that cyclophilin A is essential for cyclosporine-mediated immunosuppression, as shown by the resistance of cyclophilin A-deficient mice to the drug. The findings clarify specificity in calcineurin inhibitor mechanisms and inform experimental approaches in transplantation immunology and autoimmune disease models.

• Ridaforolimus (Deforolimus): Applied mTOR Inhibition in Canc

  2026-04-22

  Ridaforolimus (Deforolimus) delivers robust, selective mTOR pathway inhibition, empowering reproducible workflows in cancer biology and angiogenesis studies. This guide unpacks protocol best practices, troubleshooting, and how recent machine learning advances in senolytics inform applied experimental design.

• Adipose-Neural Axis and Cardiac Arrhythmias: New Mechanistic

  2026-04-22

  Fan et al. (2024) provide compelling evidence that the adipose-neural axis, particularly the interplay between leptin and neuropeptide Y signaling, contributes to arrhythmogenesis in cardiac tissue. Their stem cell-based coculture model elucidates new intervention targets, with implications for translational research in arrhythmia and neurocardiac modulation.

• Lanabecestat (AZD3293): Precision BACE1 Inhibition in Alzhei

  2026-04-21

  Lanabecestat (AZD3293) empowers researchers to selectively inhibit BACE1 with nanomolar potency, enabling precise modulation of amyloid-beta production in preclinical Alzheimer’s models. Recent evidence supports moderate, synaptic-sparing dosing strategies, making this APExBIO compound a gold standard for translational workflows targeting the amyloidogenic pathway.

15299 records 1/1020 page Next 12345 下5页 Last page